A Study Of Galcanezumab In Participants With Episodic Cluster Headache
Trial ID or NCT#
Status
Purpose
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as Galcanezumab in participants with episodic cluster headaches.
Official Title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache
Eligibility Criteria
- - Have a diagnosis of cluster headache as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines with a history of episodic cluster headache with at least two cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of >=1 month. - Participants are able to distinguish cluster headache attacks from other headaches.
- - Current enrollment in or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device. - Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP) antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF). - Are taking indomethacin and/or are suspected of having another distinct trigeminal autonomic cephalalgia. - A history of migraine variants that could implicate or could be confused with ischemia. - Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins. - A history or presence of other medical illness that indicates a medical problem that would preclude study participation. - Evidence of significant active or unstable psychiatric disease, in the opinion of the investigator. - Women who are pregnant or nursing.
Contact us to find out if this trial is right for you.
Contact
650-723-5184
View on ClinicalTrials.gov